Venus Remedies Limited

Venus Remedies Limited, established on September 15, 1989, is a publicly listed Indian pharmaceutical company headquartered in Panchkula, Haryana. The company operates under the Corporate Identification Number (CIN) L24232CH1989PLC009705 and is registered with the Registrar of Companies, Chandigarh. It is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 526953 and on the National Stock Exchange (NSE) under VENUSREM. As of March 13, 2026, Venus Remedies Limited's stock price was ₹927.50, reflecting a market capitalization of approximately ₹12.40 billion.

In the fiscal year 2025, the company reported a revenue of ₹6.48 billion, marking an 8.5% increase from the previous year. The net income for the same period was ₹762.85 million, a significant 118.8% rise. Venus Remedies Limited employs approximately 1,298 professionals, underscoring its substantial workforce dedicated to pharmaceutical manufacturing and research.

Venus Remedies Limited operates state-of-the-art manufacturing facilities in Panchkula, Haryana, and Baddi, Himachal Pradesh, India. These facilities are certified by globally recognized standards, including EU-GMP and WHO-GMP, ensuring the highest quality and safety in their products. The company also has a manufacturing plant in Werne, Germany, further expanding its global production capabilities. These facilities specialize in the development and manufacturing of innovative and high-quality fixed-dosage injectable solutions, catering to a diverse range of therapeutic areas.

The leadership team at Venus Remedies Limited comprises seasoned professionals with extensive experience in the pharmaceutical industry. Pawan Chaudhary serves as the Chairman and Managing Director, overseeing the company's strategic direction and operations. Ashutosh Jain holds the position of Chief Executive Officer and Whole-Time Director, leading the company's legal and regulatory departments. Manu Chaudhary is the Joint Managing Director and Head of Research, Development, and Operations, playing a pivotal role in the company's R&D initiatives. Peeyush Jain serves as the Deputy Managing Director and Head of Indian Marketing Operations, focusing on expanding the company's market presence within India. Akshansh Chaudhary is the Chief Technology Officer and Executive Director, driving technological advancements and innovation within the company.

Venus Remedies Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has secured over 500 marketing authorizations from both regulated and emerging markets, reflecting its robust global footprint. In the United States, Venus Remedies Limited has received Qualified Infectious Disease Product (QIDP) designation from the FDA for its novel antibiotic formulation VRP-034, highlighting its commitment to addressing antimicrobial resistance. The company's manufacturing facilities are certified by EU-GMP and WHO-GMP standards, ensuring compliance with stringent regulatory requirements in these regions.

Venus Remedies Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality is demonstrated by its WHO prequalification, which facilitates access to these markets by meeting international standards. This expansion is supported by the company's diverse portfolio of research products, both commercialized and in the pipeline, catering to the unique healthcare needs of these regions.

Venus Remedies Limited's geographic strategy emphasizes diversification across multiple regions, mitigating concentration risk and enhancing global market presence. The company's operations span over 90 countries, including Europe, Australia, Africa, Asia-Pacific, Latin America, and the Middle East. This broad geographic reach allows Venus Remedies Limited to leverage growth opportunities in various markets while maintaining a balanced risk profile.

Venus Remedies Limited has made significant strides in the U.S. market, with its novel antibiotic formulation VRP-034 receiving Qualified Infectious Disease Product (QIDP) designation from the FDA. This designation underscores the company's commitment to addressing critical healthcare challenges. The company's manufacturing facilities are registered with the FDA, and it has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), reflecting its active engagement in the U.S. pharmaceutical market. The facilities have undergone FDA inspections, ensuring compliance with U.S. regulatory standards.

Venus Remedies Limited's manufacturing facilities hold certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP) and the European Union's Good Manufacturing Practices (EU-GMP). These certifications affirm the company's adherence to international quality standards, facilitating access to regulated markets and reinforcing its reputation for producing high-quality pharmaceutical products.

In India, Venus Remedies Limited operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company holds manufacturing licenses issued by the CDSCO, ensuring compliance with national pharmaceutical regulations. Additionally, Venus Remedies Limited has obtained approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export activities and adherence to Indian regulatory requirements.

As of March 28, 2026, there are no publicly available records indicating that Venus Remedies Limited has received any Form 483 observations, warning letters, or import alerts from regulatory authorities. This absence suggests a favorable compliance history with regulatory agencies.

Venus Remedies Limited operates in a competitive landscape with several key players in the pharmaceutical industry. In the injectable antibiotics segment, the company faces competition from global pharmaceutical giants such as Pfizer, Merck, and Novartis. However, Venus Remedies Limited distinguishes itself through its specialized focus on antimicrobial resistance and oncology, areas where it holds a leading position. The company's portfolio concentration, with the top five products accounting for 73.9% of its total export value, indicates a strategic focus on high-demand therapeutic areas.

Venus Remedies Limited's key differentiators include its strong emphasis on research and development, particularly in the fields of antimicrobial resistance and oncology. The company has secured over 130 patents, reflecting its commitment to innovation. Additionally, Venus Remedies Limited's manufacturing facilities are certified by WHO-GMP and EU-GMP standards, ensuring compliance with international quality benchmarks. The company's diverse product portfolio, with a focus on injectable solutions, caters to a wide range of therapeutic areas, enhancing its market appeal.

Venus Remedies Limited's current strategic direction centers on the development and manufacturing of generic pharmaceuticals, with a particular emphasis on injectable formulations. The company's focus on antimicrobial resistance and oncology positions it as a leader in these specialized therapeutic areas. Looking ahead, Venus Remedies Limited aims to expand its presence in both regulated and emerging markets, leveraging its R&D capabilities and manufacturing expertise to drive growth.

Venus Remedies Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $86.4 million USD and 3,586 shipments across 29 products in six therapeutic categories. The company's top five products—Meropenem, Imipenem, Enoxaparin, Ceftriaxone, and Paclitaxel—account for 73.9% of its total export value, indicating a consistent and reliable supply of these key products. The company's adherence to international quality standards, as evidenced by its WHO-GMP and EU-GMP certifications, further underscores its reliability as a supplier.

Importers should verify the following certifications when considering Venus Remedies Limited as a supplier:

• FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA).

• WHO-GMP Certification: Ensure the company holds Good Manufacturing Practices certification from the World Health Organization.

• EU-GMP Certification: Verify the company's compliance with European Union Good Manufacturing Practices.

• ISO Certifications: Check for relevant International Organization for Standardization certifications that pertain to pharmaceutical manufacturing.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Venus Remedies Limited directly.

When conducting due diligence on Venus Remedies Limited, consider the following steps:

• Regulatory Compliance: Verify the company's certifications, including FDA, WHO-GMP, EU-GMP, and ISO